Literature DB >> 34783094

Choosing clinically interpretable summary measures and robust analytic procedures for quantifying the treatment difference in comparative clinical studies.

Zachary R McCaw1, Lu Tian2, Jiawei Wei3, Brian Lee Claggett4, Frank Bretz5,6, Garrett Fitzmaurice7,8, Lee-Jen Wei8.   

Abstract

Entities:  

Year:  2021        PMID： 34783094      PMCID： PMC8687139          DOI： 10.1002/sim.8971

Source DB:  PubMed          Journal:  Stat Med        ISSN： 0277-6715            Impact factor:   2.373


× No keyword cloud information.
  28 in total

1.  Estimands in clinical trials - broadening the perspective.

Authors:  Mouna Akacha; Frank Bretz; Stephen Ruberg
Journal:  Stat Med       Date:  2016-07-19       Impact factor: 2.373

2.  Restricted Mean Survival Time as a Measure to Interpret Clinical Trial Results.

Authors:  Dae Hyun Kim; Hajime Uno; Lee-Jen Wei
Journal:  JAMA Cardiol       Date:  2017-11-01       Impact factor: 14.676

3.  Deviation from the Proportional Hazards Assumption in Randomized Phase 3 Clinical Trials in Oncology: Prevalence, Associated Factors, and Implications.

Authors:  Lorenzo Trippa; Brian M Alexander; Rifaquat Rahman; Geoffrey Fell; Steffen Ventz; Andrea Arfé; Alyssa M Vanderbeek
Journal:  Clin Cancer Res       Date:  2019-07-25       Impact factor: 12.531

4.  Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio.

Authors:  Kyongsun Pak; Hajime Uno; Dae Hyun Kim; Lu Tian; Robert C Kane; Masahiro Takeuchi; Haoda Fu; Brian Claggett; Lee-Jen Wei
Journal:  JAMA Oncol       Date:  2017-12-01       Impact factor: 31.777

5.  Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves.

Authors:  Patricia Guyot; A E Ades; Mario J N M Ouwens; Nicky J Welton
Journal:  BMC Med Res Methodol       Date:  2012-02-01       Impact factor: 4.615

6.  Remdesivir for 5 or 10 Days in Patients with Severe Covid-19.

Authors:  Jason D Goldman; David C B Lye; David S Hui; Kristen M Marks; Raffaele Bruno; Rocio Montejano; Christoph D Spinner; Massimo Galli; Mi-Young Ahn; Ronald G Nahass; Yao-Shen Chen; Devi SenGupta; Robert H Hyland; Anu O Osinusi; Huyen Cao; Christiana Blair; Xuelian Wei; Anuj Gaggar; Diana M Brainard; William J Towner; Jose Muñoz; Kathleen M Mullane; Francisco M Marty; Karen T Tashima; George Diaz; Aruna Subramanian
Journal:  N Engl J Med       Date:  2020-05-27       Impact factor: 91.245

7.  Challenges in Assessing the Impact of the COVID-19 Pandemic on the Integrity and Interpretability of Clinical Trials.

Authors:  Mouna Akacha; Janice Branson; Frank Bretz; Bharani Dharan; Paul Gallo; Insa Gathmann; Robert Hemmings; Julie Jones; Dong Xi; Emmanuel Zuber
Journal:  Stat Biopharm Res       Date:  2020-08-17       Impact factor: 1.452

8.  Joint analysis of duration of ventilation, length of intensive care, and mortality of COVID-19 patients: a multistate approach.

Authors:  Derek Hazard; Klaus Kaier; Maja von Cube; Marlon Grodd; Lars Bugiera; Jerome Lambert; Martin Wolkewitz
Journal:  BMC Med Res Methodol       Date:  2020-08-11       Impact factor: 4.615

9.  Under a Black Cloud Glimpsing a Silver Lining: Comment on Statistical Issues and Recommendations for Clinical Trials Conducted During the COVID-19 Pandemic.

Authors:  Rob Hemmings
Journal:  Stat Biopharm Res       Date:  2020-07-14       Impact factor: 1.452

10.  Comment on "Statistical Issues and Recommendations for Clinical Trials Conducted During the COVID-19 Pandemic".

Authors:  Sylva H Collins; Mark S Levenson
Journal:  Stat Biopharm Res       Date:  2020-07-06       Impact factor: 1.452
View more
  1 in total

1.  Pitfall in the Design and Analysis of Comparative Oncology Trials With a Time-to-Event Endpoint and Recommendations.

Authors:  Zachary R McCaw; Dae Hyun Kim; Lee-Jen Wei
Journal:  JNCI Cancer Spectr       Date:  2022-01-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.